{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:31:03Z","timestamp":1793579463909,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001862","name":"the Swedish Research Council","doi-asserted-by":"crossref","award":["2019-02019"],"award-info":[{"award-number":["2019-02019"]}],"id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]},{"name":"between the Swedish government and the county councils concerning economic support of research and education of doctors","award":["ALFGBG-966187"],"award-info":[{"award-number":["ALFGBG-966187"]}]},{"name":"the Swedish Heart and Lung Foundation","award":["2019-0532"],"award-info":[{"award-number":["2019-0532"]}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The association between type 2 diabetes (T2D) and the development of cardiac arrhythmias and conduction disturbances has not been extensively studied. Arrhythmia was defined as atrial fibrillation and flutter (AF\/AFl), ventricular tachycardia (VT) and ventricular fibrillation (VF), and conduction abnormality as sinus node disease (SND), atrioventricular (AV) block or pacemaker implantation, and intraventricular conduction blocks (IVCB). Incidence rates and Cox regression were used to compare outcomes, and to assess optimal levels for cardiometabolic risk factors and risk associated with multifactorial risk factor control (i.e., HbA1c, LDL-C, systolic blood pressure (SBP), BMI and eGFR), between patients with versus without T2D. The analyses included data from 617,000 patients with T2D and 2,303,391 matched controls. Patients with diabetes and the general population demonstrated a gradual increase in rates for cardiac conduction abnormalities and virtually all age-groups for AF\/AFI showed increased incidence during follow-up. For patients with versus without T2D, risks for cardiac arrhythmias were higher, including for AF\/AFl (HR 1.17, 95% CI 1.16\u20131.18), the composite of SND, AV-block or pacemaker implantation (HR 1.40, 95% CI 1.37\u20131.43), IVCB (HR 1.23, 95% CI 1.18\u20131.28) and VT\/VF (HR 1.08, 95% CI 1.04\u20131.13). For patients with T2D who had selected cardiometabolic risk factors within target ranges, compared with controls, risk of arrythmia and conduction abnormalities for T2D vs not were: AF\/AFl (HR 1.09, 95% CI 1.05\u20131.14), the composite of SND, AV-block or pacemaker implantation (HR 1.06, 95% CI 0.94\u20131.18), IVCB (HR 0.80, 95% CI 0.60\u20130.98), and for VT\/VF (HR 0.97, 95% CI 0.80\u20131.17). Cox models showed a linear risk increase for SBP and BMI, while eGFR showed a U-shaped association. Individuals with T2D had a higher risk of arrhythmias and conduction abnormalities than controls, but excess risk associated with T2D was virtually not evident among patients with T2D with all risk factors within target range. BMI, SBP and eGFR displayed significant associations with outcomes among patients with T2D.<\/jats:p>","DOI":"10.1038\/s41598-023-27941-5","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T06:02:49Z","timestamp":1674280969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes"],"prefix":"10.1038","volume":"13","author":[{"given":"Araz","family":"Rawshani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmir","family":"Omerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Redfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Bergfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Eliasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidin","family":"Rawshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"issue":"15","key":"27941_CR1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani, A. et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N. Engl. J. Med. 376(15), 1407\u20131418 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"27941_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/2047487315599892","volume":"23","author":"JL Pallisgaard","year":"2016","unstructured":"Pallisgaard, J. L. et al. Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study. Eur. J. Prev. Cardiol. 23(6), 621\u2013627 (2016).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"8A","key":"27941_CR3","doi-asserted-by":"publisher","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","volume":"82","author":"WB Kannel","year":"1998","unstructured":"Kannel, W. B., Wolf, P. A., Benjamin, E. J. & Levy, D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am. J. Cardiol. 82(8A), 2N-9N (1998).","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"27941_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379(7), 633\u2013644 (2018).","journal-title":"N. Engl. J. Med."},{"key":"27941_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379, 633\u2013644 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"27941_CR6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ahj.2010.02.005","volume":"159","author":"AM Chamberlain","year":"2010","unstructured":"Chamberlain, A. M. et al. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J. 159(5), 850\u2013856 (2010).","journal-title":"Am. Heart J."},{"issue":"19","key":"27941_CR7","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1001\/jama.2013.280521","volume":"310","author":"HS Abed","year":"2013","unstructured":"Abed, H. S. et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial. JAMA 310(19), 2050\u20132060 (2013).","journal-title":"JAMA"},{"issue":"21","key":"27941_CR8","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.jacc.2014.09.028","volume":"64","author":"RK Pathak","year":"2014","unstructured":"Pathak, R. K. et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. J. Am. Coll. Cardiol. 64(21), 2222\u20132231 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"20","key":"27941_CR9","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","volume":"65","author":"RK Pathak","year":"2015","unstructured":"Pathak, R. K. et al. Long-Term effect of goal-directed weight management in an atrial fibrillation cohort: A long-term follow-up study (LEGACY). J. Am. Coll. Cardiol. 65(20), 2159\u20132169 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"27941_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker, T. A. et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: Insights from the DECLARE-TIMI 58 trial. Circulation 141(15), 1227\u20131234 (2020).","journal-title":"Circulation"},{"issue":"1","key":"27941_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-019-0983-1","volume":"19","author":"S Seyed Ahmadi","year":"2020","unstructured":"Seyed Ahmadi, S., Svensson, A. M., Pivodic, A., Rosengren, A. & Lind, M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: A Swedish cohort study. Cardiovasc. Diabetol. 19(1), 9 (2020).","journal-title":"Cardiovasc. Diabetol."},{"issue":"31","key":"27941_CR12","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1093\/eurheartj\/eht142","volume":"34","author":"JA Beckman","year":"2013","unstructured":"Beckman, J. A., Paneni, F., Cosentino, F. & Creager, M. A. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II. Eur. Heart J. 34(31), 2444\u20132452 (2013).","journal-title":"Eur. Heart J."},{"issue":"9","key":"27941_CR13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.amjcard.2006.12.042","volume":"99","author":"HJ Willens","year":"2007","unstructured":"Willens, H. J. et al. Effects of weight loss after bariatric surgery on epicardial fat measured using echocardiography. Am. J. Cardiol. 99(9), 1242\u20131245 (2007).","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"27941_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2011.10.014","volume":"220","author":"R Nakazato","year":"2012","unstructured":"Nakazato, R. et al. Weight change modulates epicardial fat burden: A 4-year serial study with non-contrast computed tomography. Atherosclerosis 220(1), 139\u2013144 (2012).","journal-title":"Atherosclerosis"},{"issue":"5","key":"27941_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/obr.12270","volume":"16","author":"SW Rabkin","year":"2015","unstructured":"Rabkin, S. W. & Campbell, H. Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies: A systematic review and meta-analysis. Obes. Rev. 16(5), 406\u2013415 (2015).","journal-title":"Obes. Rev."},{"key":"27941_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cca.2013.03.005","volume":"421","author":"CP Fu","year":"2013","unstructured":"Fu, C. P. et al. Effects of weight loss on epicardial adipose tissue thickness and its relationship between serum soluble CD40 ligand levels in obese men. Clin. Chim. Acta 421, 98\u2013103 (2013).","journal-title":"Clin. Chim. Acta"},{"key":"27941_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijcard.2018.06.106","volume":"274","author":"V Parisi","year":"2019","unstructured":"Parisi, V. et al. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue. Int. J. Cardiol. 274, 326\u2013330 (2019).","journal-title":"Int. J. Cardiol."},{"issue":"19","key":"27941_CR18","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.jacc.2012.12.051","volume":"61","author":"N Alexopoulos","year":"2013","unstructured":"Alexopoulos, N. et al. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: A substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). J. Am. Coll. Cardiol. 61(19), 1956\u20131961 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"27941_CR19","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.amjcard.2015.07.067","volume":"116","author":"F Soucek","year":"2015","unstructured":"Soucek, F. et al. Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation. Am. J. Cardiol. 116(9), 1443\u20131446 (2015).","journal-title":"Am. J. Cardiol."},{"key":"27941_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jnutbio.2017.06.008","volume":"48","author":"TA Pinheiro","year":"2017","unstructured":"Pinheiro, T. A. et al. Obesity and malnutrition similarly alter the renin\u2013angiotensin system and inflammation in mice and human adipose. J. Nutr. Biochem. 48, 74\u201382 (2017).","journal-title":"J. Nutr. Biochem."},{"issue":"4","key":"27941_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/cphy.c160031","volume":"7","author":"M Pahlavani","year":"2017","unstructured":"Pahlavani, M., Kalupahana, N. S., Ramalingam, L. & Moustaid-Moussa, N. Regulation and functions of the renin\u2013angiotensin system in white and brown adipose tissue. Compr. Physiol. 7(4), 1137\u20131150 (2017).","journal-title":"Compr. Physiol."},{"key":"27941_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson, J. F. et al. External review and validation of the Swedish national inpatient register. BMC Public Health 11, 450 (2011).","journal-title":"BMC Public Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27941-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27941-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27941-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T06:08:54Z","timestamp":1674281334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27941-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["27941"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-27941-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1969015\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Deepak L. Bhatt discloses the following relationships\u2014Advisory Board: Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: Boston VA Research Institute, DRS.LINQ (stock options), Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Data Monitoring Committees: Acesion Pharma, Assistance Publique-H\u00f4pitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi\/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence\/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today\u2019s Intervention), Society of Cardiovascular Patient Care (Secretary\/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald\u2019s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Takeda. Dr. McGuire, receiving executive committee fees and consulting fees from Boehringer Ingelheim, Sanofi US, and AstraZeneca, data monitoring committee fees from CSL Behring, executive committee fees, consulting fees, and advisory board fees from Lilly USA and Novo Nordisk, executive committee fees from Lexicon and Eisai, steering committee fees from Esperion, consulting fees from Metavant, Applied Therapeutics, Bayer and Afimmune, and advisory board fees from Pfizer and Merck Sharp and Dohme; Dr. Sattar, has consulted for Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi, MSD, Novartis, Novo Nordisk, Pfizer, and Sanofi; and received grant support from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics outside the submitted work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1192"}}